MORRISVILLE, N.C.--(BUSINESS WIRE)--Worldwide Clinical Trials, Inc. (Worldwide), an award-winning, full-service, midsize, global CRO, has announced two additions to its U.S. Business Development team. CRO industry experts Giovanna Chan and Cara Staley have joined the company to lead the western and eastern U.S. business development regions, respectively.
Chan and Staley are Worldwide’s latest high-profile hires in recent months. They will report to Sara Davis, who joined the organization in June and was recently promoted to lead the company’s global commercial team.
The growing team signals the company’s continued commitment to investing in the resources small to midsize pharmaceutical and biopharmaceutical organizations demand from their CRO partner. In its recently released annual industry survey, Worldwide captured insights from more than 350 executives representing approximately 170 of these organizations, who indicated that their expectations of CRO relationships continue to evolve.
“Worldwide’s growth is a testament to how well we deliver to small and midsize companies, as well as large pharma organizations’ demands. Sponsors tell us they need their CRO partner to scale to manage global development portfolios, offer deep expertise and operational excellence to challenge the status quo, and innovate to reduce the time and cost of drug development,” Davis said. “As strategic and innovative leaders with proven ability to grow therapeutically focused CRO businesses, Giovanna Chan and Cara Staley are ideal fits for our target market. Their partnership approach and strong sales acumen will help accelerate our momentum as we continue to strive toward our goal to be the world’s best midsize CRO."
Now Vice President, Business Development, U.S. – West, Chan joins Worldwide from PRA Health Sciences where she was a senior director in charge of business development activities across a West Coast territory, including Los Angeles, San Diego, San Francisco and Seattle. She has also held business development leadership roles with Chiltern (formerly Theorem Clinical Research) and CSC Life Sciences.
As Vice President, Business Development, U.S. – East, Staley brings considerable experience in positioning both early stage and established organizations to succeed in the life sciences industry. She is a tenured, top-producing CRO industry veteran and last served as a senior director responsible for business development at PSI-CRO. Prior to her work in the CRO industry, Staley founded a nonprofit for brain tumor research.
For more background on Chan, Staley and the Worldwide team, visit www.worldwide.com.
About Worldwide Clinical Trials
Worldwide Clinical Trials employs more than 1,600 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia, and Asia. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval and real-world evidence, we provide world-class, full-service drug development services. With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, immune-mediated inflammatory disorders (IMID), oncology and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO. For more information, visit http://www.worldwide.com.